Although the clinical outcome in diffuse large B-cell lymphoma (DLBCL) has dramatically improved over the last decades and will likely improve further with the introduction of novel specific anti-cancer agents and therapeutic approaches, relapsed/refractory DLBCL remains a major cause of morbidity and mortality.
Particularly, the management of patients ineligible for high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT) or with disease relapsing after HDC-ASCT is very difficult and the only remaining treatment option for these patients includes participation in phase 1/2 clinical trials with novel experimental agents or palliative therapy.
1,2 Thus, for the remainder of these patients with relapsed/refractory and high-risk biological subtypes of DLBCL, further improvements in therapy and novel therapeutic strategies are urgently needed. Data emerging from early clinical trials demonstrated that lenalidomide has a significant activity against relapsed/refractory DLBCL either as monotherapy or in association with rituximab.
3-7
Herein we report updated long-term results of a single-center phase II trial on the combination of lenalidomide and rituximab (induction phase, four cycles) plus lenalidomide maintenance for 8 months. Response assessment was made following the revised response criteria for malignant lymphomas and endpoints (namely, overall, progression free and disease free survivals) were defined accordingly. with a disease free survival of 75% at 6 years as 2/8 patients progressed and died due to lymphoma (Figure 1 ).
Regarding the long term safety, no second malignancies occurred. Table 1 summarizes the characteristics of the 6 long-term responders.
According to the cell of origin (COO) of DLBCL, the material was sufficient and evaluable (according to immunohistochemistry method defined by Hans criteria) 10 The value of a maintenance phase in addition to induction as well as the optimal length of induction remain undefined and worthy of additional investigation. 
